Cargando…

High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor

There is limited data on miRNA expression in pancreatic neuroendocrine tumors (PanNETs). In this study, we aimed to identify miRNAs that could be potential prognostic biomarkers of PanNETs in patients who underwent curative surgery. For miRNA target screening, 2 primary PanNETs and corresponding liv...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yoon Suk, Kim, Haeryoung, Kim, Hyoung Woo, Lee, Jong-Chan, Paik, Kyu-Hyun, Kang, Jingu, Kim, Jaihwan, Yoon, Yoo-Seok, Han, Ho-Seong, Sohn, Insuk, Cho, Jeonghee, Hwang, Jin-Hyeok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058906/
https://www.ncbi.nlm.nih.gov/pubmed/26683934
http://dx.doi.org/10.1097/MD.0000000000002224
_version_ 1782459332846157824
author Lee, Yoon Suk
Kim, Haeryoung
Kim, Hyoung Woo
Lee, Jong-Chan
Paik, Kyu-Hyun
Kang, Jingu
Kim, Jaihwan
Yoon, Yoo-Seok
Han, Ho-Seong
Sohn, Insuk
Cho, Jeonghee
Hwang, Jin-Hyeok
author_facet Lee, Yoon Suk
Kim, Haeryoung
Kim, Hyoung Woo
Lee, Jong-Chan
Paik, Kyu-Hyun
Kang, Jingu
Kim, Jaihwan
Yoon, Yoo-Seok
Han, Ho-Seong
Sohn, Insuk
Cho, Jeonghee
Hwang, Jin-Hyeok
author_sort Lee, Yoon Suk
collection PubMed
description There is limited data on miRNA expression in pancreatic neuroendocrine tumors (PanNETs). In this study, we aimed to identify miRNAs that could be potential prognostic biomarkers of PanNETs in patients who underwent curative surgery. For miRNA target screening, 2 primary PanNETs and corresponding liver metastases were screened for miRNA expression by the NanoString nCounter analysis. Candidate miRNAs were selected by ≥2-fold difference of expression between metastatic versus primary tumor. For miRNA target validation, quantitative real-time PCR was performed for candidate miRNAs on 37 PanNETs and matched nonneoplastic pancreata, and the miRNA levels were correlated with the clinicopathological features and patient survival data. Eight miRNAs (miRNA-27b, -122, -142–5p, -196a, -223, -590–5p, -630, and -944) were selected as candidate miRNAs. Only miR-196a level was significantly associated with stage, and mitotic count. When PanNETs were stratified into high (n = 10) and low (n = 27) miRNA-196a expression groups, miRNA-196a-high PanNETs were significantly associated with advanced pathologic T stage (50.0% vs 7.4%), N stage (50.0% vs 3.7%), higher mitotic counts (60.0% vs 3.7%), and higher Ki-67-labeling indices (60.0% vs 22.2%). In addition, high miRNA-196a expression was significantly associated with decreased overall survival (P = 0.046) and disease-free survival (P < 0.001) during a median follow-up of 37.9 months with the hazard ratio for recurrence of 16.267 (95% confidence interval = 1.732–153.789; P = 0.015). MiRNA-196a level may be a promising prognostic marker of recurrence in resected PanNETs, although further experimental investigation would be required.
format Online
Article
Text
id pubmed-5058906
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-50589062016-11-01 High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor Lee, Yoon Suk Kim, Haeryoung Kim, Hyoung Woo Lee, Jong-Chan Paik, Kyu-Hyun Kang, Jingu Kim, Jaihwan Yoon, Yoo-Seok Han, Ho-Seong Sohn, Insuk Cho, Jeonghee Hwang, Jin-Hyeok Medicine (Baltimore) 3700 There is limited data on miRNA expression in pancreatic neuroendocrine tumors (PanNETs). In this study, we aimed to identify miRNAs that could be potential prognostic biomarkers of PanNETs in patients who underwent curative surgery. For miRNA target screening, 2 primary PanNETs and corresponding liver metastases were screened for miRNA expression by the NanoString nCounter analysis. Candidate miRNAs were selected by ≥2-fold difference of expression between metastatic versus primary tumor. For miRNA target validation, quantitative real-time PCR was performed for candidate miRNAs on 37 PanNETs and matched nonneoplastic pancreata, and the miRNA levels were correlated with the clinicopathological features and patient survival data. Eight miRNAs (miRNA-27b, -122, -142–5p, -196a, -223, -590–5p, -630, and -944) were selected as candidate miRNAs. Only miR-196a level was significantly associated with stage, and mitotic count. When PanNETs were stratified into high (n = 10) and low (n = 27) miRNA-196a expression groups, miRNA-196a-high PanNETs were significantly associated with advanced pathologic T stage (50.0% vs 7.4%), N stage (50.0% vs 3.7%), higher mitotic counts (60.0% vs 3.7%), and higher Ki-67-labeling indices (60.0% vs 22.2%). In addition, high miRNA-196a expression was significantly associated with decreased overall survival (P = 0.046) and disease-free survival (P < 0.001) during a median follow-up of 37.9 months with the hazard ratio for recurrence of 16.267 (95% confidence interval = 1.732–153.789; P = 0.015). MiRNA-196a level may be a promising prognostic marker of recurrence in resected PanNETs, although further experimental investigation would be required. Wolters Kluwer Health 2015-12-18 /pmc/articles/PMC5058906/ /pubmed/26683934 http://dx.doi.org/10.1097/MD.0000000000002224 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 3700
Lee, Yoon Suk
Kim, Haeryoung
Kim, Hyoung Woo
Lee, Jong-Chan
Paik, Kyu-Hyun
Kang, Jingu
Kim, Jaihwan
Yoon, Yoo-Seok
Han, Ho-Seong
Sohn, Insuk
Cho, Jeonghee
Hwang, Jin-Hyeok
High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
title High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
title_full High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
title_fullStr High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
title_full_unstemmed High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
title_short High Expression of MicroRNA-196a Indicates Poor Prognosis in Resected Pancreatic Neuroendocrine Tumor
title_sort high expression of microrna-196a indicates poor prognosis in resected pancreatic neuroendocrine tumor
topic 3700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058906/
https://www.ncbi.nlm.nih.gov/pubmed/26683934
http://dx.doi.org/10.1097/MD.0000000000002224
work_keys_str_mv AT leeyoonsuk highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT kimhaeryoung highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT kimhyoungwoo highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT leejongchan highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT paikkyuhyun highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT kangjingu highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT kimjaihwan highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT yoonyooseok highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT hanhoseong highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT sohninsuk highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT chojeonghee highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor
AT hwangjinhyeok highexpressionofmicrorna196aindicatespoorprognosisinresectedpancreaticneuroendocrinetumor